Search

Deals with a study which measured the boron concentration profiles in rapid thermally annealed silicon and strained Si[sub1] - [subx]Ge[subx] epitaxial layers during rapid thermal annealing. Advantages of heterojunction bipolar transistors; Profile measurements for boron concentrations; Derivation of the diffusion model in heterostructures.

Background: Nearly 10 years after its introduction into the market, the significance of lacosamide in genetic generalized epilepsies is still unclear. Its new mode of action may qualify lacosamide as a therapeutic agent in this entity, but only a limited number of cases have been published so far. Aim: To describe the efficacy of lacosamide as treatment in a patient with the absence status epilepticus. Method: We report on a 28‐year‐old woman with genetic generalized epilepsy who suffered recurrent absence status epilepticus during video‐EEG‐monitoring. After treatment failure of first‐ and second‐line medication, lacosamide was administered. The outcome in this patient was evaluated, and a systematic literature review was performed for the use of lacosamide in the absence status epilepticus. Results: After application of 400 mg lacosamide intravenously, the absence status epilepticus terminated within 30 minutes. No further seizures or epileptiform discharges reoccurred until the end of video‐EEG‐Monitoring 3 days later. Conclusions: The role of lacosamide as a therapeutic option in patients with the absence status epilepticus is unclear. Only two cases have been reported so far with conflicting results. Further randomized controlled studies are required to validate the relevance of lacosamide as treatment for status epilepticus in genetic generalized and the absence epilepsy. [ABSTRACT FROM AUTHOR]

Purpose: To evaluate prospectively the relationship between appetite, food composition, nutritional habits and weight loss following administration of topiramate (TPM) and to identify predictors for TPM induced weight loss. Methods: 22 patients with epilepsy who were started on TPM were prospectively followed for 6 months and contacted again after a mean follow-up time of 37.1 months. Results: Body mass index (BMI) loss occurred in 59% of patients, with a mean weight loss of 9.5 kg after 6 months while receiving TPM without further weight loss at the long term follow-up. Weight loss was associated with reduction in appetite without affecting food composition. Predictors for BMI loss after 6 months were high initial BMI and body fat. After 3 weeks of treatment with TPM, the recorded parameters did not predict BMI loss but at 3 months, weight loss, reduction of appetite and amount of food intake were predictive for the amount of BMI loss after 6 months. [ABSTRACT FROM AUTHOR]

We report the CT findings of a solitary fibrous tumor of the orbit. The radiologic features included relatively homogeneous contrast enhancement and smooth remodelling of the bones of the orbit, findings consistent with the benign nature of this relatively rare tumor. [ABSTRACT FROM AUTHOR]

We have developed a new electronic (inelastic) stopping model for low-energy implanted ions which explicitly accounts for the effect of the local variation of the electron density between the lattice atoms in the silicon crystal target material on the amount and rate of energy loss due to electronic processes. Designed for incorporation into Monte Carlo simulation codes, this model more accurately predicts the energy loss of ions due to electronic processes, and it provides significantly better agreement with experimental profiles of boron implanted into single-crystal silicon over a wide range of energies and incident angles compared with the agreement obtained with other electronic stopping models. [ABSTRACT FROM AUTHOR]

In 2006, levetiracetam was approved as the first of the newer anticonvulsive drugs as an intravenous formulation (ivLEV) for patients with epileptic seizures who are unable to take oral medication. We report our experience with the use of ivLEV for the treatment of 18 episodes of benzodiazepine refractory focal status epilepticus (SE) in 16 patients, including four patients with secondary generalised SE. SE was controlled in all patients by the given combination of drugs; application of further antiepileptic medications after ivLEV was necessary in two episodes. No severe side effects occurred. Our data suggest that ivLEV may be an alternative for the treatment of SE in the future, even in patients that did not respond to benzodiazepines. A large prospective, randomised, controlled study is warranted to investigate the efficacy and safety of ivLEV for the treatment of SE. [ABSTRACT FROM AUTHOR]